About Microbiotica

Microbiotica develops precision live biotherapeutic products that translate microbiome science into targeted medicines. The company identifies bacterial strains linked to clinical benefit in specific patient populations, then formulates these commensal strains into oral therapies. Its lead products address immuno-oncology and inflammatory bowel disease. The approach analyses microbiome profiles from clinical trials using bioinformatics and machine learning to identify bacterial signatures linked to positive outcomes. These natural strains become defined consortia designed as monotherapies or co-therapies that enhance existing treatments, enabling responses in patients who have not benefited from conventional therapy.